Wu Allan Y, Morrow David M
J Transl Med. 2013 May 31;11:136. doi: 10.1186/1479-5876-11-136.
In an attempt to engineer a regulatory compliant form of cell assisted lipotransfer in the U.S., the authors developed Autologous Fat Transfer with In-situ Mediation (AIM) for reconstruction of a refractory surgical scar.
This method incorporates use of accepted standard procedures like autologous fat grafting and intradermal injection of NB6 collagenase to release adipose stem cells from a naturally occurring high concentration stromal vascular fraction (SVF) fat graft. To prevent off-target effects of collagenase, a hyaluronic acid and serum deactivation barrier is placed circumferentially around the operative site.
This novel protocol was well tolerated by the patient and improved scar appearance, mobility and texture. Deepest scar contour defect correction was 80% and 77% at 4 and 12 weeks respectively.
AIM appears to be a practical and viable option for scar reconstruction requiring small to moderate volume correction.
为了在美国设计一种符合监管要求的细胞辅助脂肪移植形式，作者开发了原位介导自体脂肪移植（AIM）用于修复难治性手术瘢痕。
该方法采用了自体脂肪移植和皮内注射NB6胶原酶等公认的标准程序，以从天然高浓度的基质血管成分（SVF）脂肪移植中释放脂肪干细胞。为防止胶原酶的脱靶效应，在手术部位周围环形放置透明质酸和血清失活屏障。
该新方案患者耐受性良好，瘢痕外观、活动度和质地均有改善。在4周和12周时，最深瘢痕轮廓缺陷矫正分别为80%和77%。
对于需要小至中等体积矫正的瘢痕重建，AIM似乎是一种实用且可行的选择。
